Quick Answer
HCW Biologics Inc. reported Stockholders Equity of $2.76 million for the year ending 2025.
- HCW Biologics Inc. showed an increase of +140.8% in Stockholders Equity from 2024 to 2025.
- This data is from HCW Biologics Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$12.33 million | Q2 2020: -$15.38 million | Q3 2020: -$18.37 million | Q1 2021: -$20.03 million | Q2 2021: -$23.24 million | Q3 2021: $54.01 million | Q1 2022: $49.40 million | Q2 2022: $46.17 million | Q3 2022: $42.56 million | Q1 2023: $32.62 million | Q2 2023: $28.59 million | Q3 2023: $23.87 million | Q1 2024: $8.74 million | Q2 2024: -$6.30 million | Q3 2024: -$9.97 million | Q1 2025: -$8.56 million | Q2 2025: -$52.0 thousand | Q3 2025: -$2.11 million.
- Over the full 7 years of available data (2019 to 2025), HCW Biologics Inc.'s Stockholders Equity has grown by 128.6%.
- Historical annual values: Fiscal year 2025: $2.76 million | Fiscal year 2024: -$6.77 million | Fiscal year 2023: $13.46 million | Fiscal year 2022: $37.43 million | Fiscal year 2021: $51.19 million | Fiscal year 2020: -$16.72 million | Fiscal year 2019: -$9.68 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: